Back to Search
GARGI KUNDU, MD
MD
Addiction Medicine (Internal Medicine) Physician
NPI: 1780641217Individual
Specialties, Licenses & Credentials
Addiction Medicine (Internal Medicine) PhysicianPrimary
Internal Medicine — Addiction Medicine
Code: 207RA0401X
11900(NH)
Research & Publications (20)
Osteopontin promotes vascular endothelial growth factor-dependent breast tumor growth and angiogenesis via autocrine and paracrine mechanisms.
PMID 18172307·Cancer Res·2008
7-preclinical
Down-regulation of osteopontin attenuates breast tumour progression in vivo.
PMID 18266970·J Cell Mol Med·2008
7-preclinical
Prostaglandin E2 regulates tumor angiogenesis in prostate cancer.
PMID 18829529·Cancer Res·2008
7-preclinical
Osteopontin: an emerging therapeutic target for anticancer therapy.
PMID 17150036·Expert Opin Ther Targets·2007
6-review
Osteopontin stimulates melanoma growth and lung metastasis through NIK/MEKK1-dependent MMP-9 activation pathways.
PMID 17786354·Oncol Rep·2007
7-preclinical
The multifaceted roles of osteopontin in cell signaling, tumor progression and angiogenesis.
PMID 17168734·Curr Mol Med·2006
6-review
The crucial role of cyclooxygenase-2 in osteopontin-induced protein kinase C alpha/c-Src/IkappaB kinase alpha/beta-dependent prostate tumor progression and angiogenesis.
PMID 16818637·Cancer Res·2006
7-preclinical
Nuclear factor inducing kinase: a key regulator in osteopontin- induced MAPK/IkappaB kinase dependent NF-kappaB-mediated promatrix metalloproteinase-9 activation.
PMID 16691505·Glycoconj J·2006
7-preclinical
Hypoxia regulates cross-talk between Syk and Lck leading to breast cancer progression and angiogenesis.
PMID 16474166·J Biol Chem·2006
7-preclinical
Osteopontin: role in cell signaling and cancer progression.
PMID 16406521·Trends Cell Biol·2006
6-review
Osteopontin: it's role in regulation of cell motility and nuclear factor kappa B-mediated urokinase type plasminogen activator expression.
PMID 16012053·IUBMB Life·2005
6-review
Antimelanomal activity of the copper(II) complexes of 1-substituted 5-amino-imidazole ligands against B16F10 mouse melanoma cells.
PMID 15125951·Bioorg Med Chem Lett·2004
7-preclinical
Matrix metalloproteinase-2: mechanism and regulation of NF-kappaB-mediated activation and its role in cell motility and ECM-invasion.
PMID 15750784·Glycoconj J·2004
7-preclinical
Nuclear factor-inducing kinase plays a crucial role in osteopontin-induced MAPK/IkappaBalpha kinase-dependent nuclear factor kappaB-mediated promatrix metalloproteinase-9 activation.
PMID 15247285·J Biol Chem·2004
7-preclinical
Osteopontin induces AP-1-mediated secretion of urokinase-type plasminogen activator through c-Src-dependent epidermal growth factor receptor transactivation in breast cancer cells.
PMID 14704150·J Biol Chem·2004
8-other
Tyrosine kinase, p56lck-induced cell motility, and urokinase-type plasminogen activator secretion involve activation of epidermal growth factor receptor/extracellular signal regulated kinase pathways.
PMID 14699120·J Biol Chem·2004
8-other
Tyrosine kinase p56lck regulates cell motility and nuclear factor kappaB-mediated secretion of urokinase type plasminogen activator through tyrosine phosphorylation of IkappaBalpha following hypoxia/reoxygenation.
PMID 14534291·J Biol Chem·2003
8-other
Osteopontin stimulates cell motility and nuclear factor kappaB-mediated secretion of urokinase type plasminogen activator through phosphatidylinositol 3-kinase/Akt signaling pathways in breast cancer cells.
PMID 12771144·J Biol Chem·2003
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 700 LAKE AVE
MANCHESTER, NH 03103 - Phone
- (603) 263-6293
Quick Facts
- NPI
- 1780641217
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile